According to many studies, low levels of high-density lipoprotein cholesterol (HDL-C) are an independent risk factor for coronary artery disease \[[@CIT0001]\]. HDL has several pleiotropic properties apart from reverse cholesterol transport; these include anti-oxidant, anti-inflammatory, anti-infectious, anti-proliferative, antithrombotic and vasodilator actions \[[@CIT0002]--[@CIT0004]\].

Randomised controlled trials, prospective and genetic studies, as well as meta-analyses have produced controversial results regarding treating low HDL-C levels \[[@CIT0005], [@CIT0006]\].

The functionality of HDL-C, as well as the role of dysfunctional HDL (dysHDL) in the prediction of cardiovascular (CV) risk has generated considerable debate. Therefore, we read with interest the Dodani *et al*. study \[[@CIT0007]\] which showed that dysHDL was significantly associated (*p* = 0.0024) with common carotid artery intima-media thickness (CCA-IMT) in 129 South Asian immigrants. Chronic inflammation transforms HDL to dysHDL \[[@CIT0004]\]. However, the authors did not mention any correlation between high sensitivity C-reactive protein levels and the quantity of dysHDL or whether routinely measured HDL-C levels correlated with CCA-IMT and if any such relationship differs from dysHDL.

It is apparent from the above, that not only the quantity, but also the quality of HDL matters (*Quantity and Quality; "Q and Q"*). As a result, there is a need for new drugs that, apart from raising HDL-C levels, can improve HDL function \[[@CIT0008], [@CIT0009]\]. Cholesterol ester transfer protein (CETP) inhibitors (anacetrapib and evacetrapib) seem to be promising \[[@CIT0006]\]. However, there is no class effect, as the development of other CETP inhibitors (torcetrapib and dalcetrapib) was discontinued \[[@CIT0006]\].

It is worth emphasizing that we are at the beginning of dysHDL research. Some issues need to be considered before confirming the potential predictive role of dysHDL \[[@CIT0004]\]. We need an easy and direct diagnostic method for dysHDL evaluation (possibly *via* measurement of highly specific microRNAs (miRs), as suggested in the DYS-HDL trial), as well as an optimal method for HDL subfraction analysis (to establish if certain subfractions are dysfunctional) \[[@CIT0002], [@CIT0010], [@CIT0011]\].

HDL carries specific miRs \[[@CIT0010], [@CIT0011]\]. Therefore, dysHDL-miRs, as well as HDL subfraction-miRs, could prove to be novel biomarkers of CV disease \[[@CIT0010], [@CIT0011]\]. Targeting HDL-miRs might also be a promising basis for drug development \[[@CIT0010], [@CIT0011]\]. It is crucial to identify the patients and conditions at the highest risk of dysHDL formation. This population might benefit most from improving HDL "Q and Q" with a potential subsequent reduction in CV disease residual risk \[[@CIT0010]--[@CIT0013]\].
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